A study of 637 Japanese women with ovarian, fallopian or primary peritoneal cancer showed that dose dense chemotherapy provided a benefit. The standard of care arm provided chemotherapy every three weeks, the dose dense arm provided one of the drugs every week and the other every three weeks. Women who were on the dose dense arm had an improvement of nine months PFS; the full OS data is not complete at this point.
American and European studies regarding dose dense chemotherapy in ovarian cancer are ongoing.
Read the article here